Indoco Remedies Reports Q1 Loss Despite Revenue Growth; Receives EU GMP Certification 5 days ago
Indoco Remedies reported a 12.5% increase in Q1 revenue to Rs 429.08 crore, but faced profitability challenges with a net loss of Rs 36.35 crore. EBITDA improved to Rs 14.80 crore. The company received EU GMP certification for its Goa Plant II, potentially opening new European market opportunities. Two subsidiaries, FPP Holding LLC and Warren Remedies Private Limited, reported losses. Management remains confident about future growth and turnaround prospects.
Indoco Remedies Secures EU GMP Compliance Certificate for Goa Plant II 5 days ago
Indoco Remedies Relieved as GST Authority Drops ₹85 Million Demand Jun 11, 2025
Indoco Remedies Secures FDA Approval for Allopurinol Tablets May 23, 2025
Indoco Remedies' AnaCipher Facility Completes FDA Inspection with One Form 483
Indoco Remedies' Clinical Research Organisation, AnaCipher, in Hyderabad, completed a U.S. FDA inspection from March 3-7, 2025. The inspection, covering clinical and bioanalytical phases of three BA/BE studies, resulted in one Form 483 observation. The company will respond within the specified timeframe. Managing Director Aditi Kare Panandikar views this as validation of their adherence to regulations and quality standards.
10Mar 25
Indoco Remedies' AnaCipher Facility Completes FDA Inspection with One Form 483 Observation
Indoco Remedies' Clinical Research Organisation, AnaCipher, in Hyderabad completed a 5-day FDA inspection from March 3-7, 2025. The inspection, covering clinical and bioanalytical phases of three BA/BE studies, resulted in one Form 483 observation. The company plans to respond within the given timeframe. Managing Director Aditi Kare Panandikar views this as validation of their adherence to regulations and quality standards.